This document provides a summary of Profarma's 4Q10 and 2010 earnings release. Some key highlights include:
- A 3.7 day reduction in cash cycle compared to 2009, resulting in lower working capital of R$22.9 million
- Positive operating cash flow for the third consecutive year of R$44.4 million
- A 3.0% increase in consolidated gross revenues to R$3.1 billion in 2010
- Net debt decreased to R$108.7 million in December 2010
3. Highlights in the Period
• A drop of 3.7 days in the Company's cash cycle when compared with 2009 (IFRS base), to 49.0 days. This is the
shortest cash cycle since 2006. This decrease resulted in a fall of about R$ 22.9 million in working capital;
• The operating cash flow was positive for the third consecutive year and amounted to R$ 44.4 million, or 1.7% of the
net operating revenue;
• The net debt stood at R$ 108.7 million in December 2010, a R$ 9.4 million decrease in relation to December 2009,
mainly due to the Company's positive operating cash generation, of about R$ 44.4 million;
• A rise of 3.0% in consolidated gross revenues year-over-year, totaling R$ 3.1 billion, highlighting the health and
beauty category, in which a sharp growth of 37.8% was recorded;
• Sales through electronic orders hit a record high and accounted for 65.3% of total sales in 2010;
• In October 2010, Profarma decided to terminate the market maker contract with Credit Suisse Brasil SA CTVM;
nevertheless, there was no drop in daily liquidity.
3